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Abstract
A Saccharomyces boulardii strain, which does not carry any auxotrophic markers, was 
transformed with knockout constructs for the genes HIS3 and ADE2 using the domi-
nant antibiotic marker genes encoding for kanamycin/G418- and nourseothricin/NATR 
resistance. Thereby, homozygous derivatives that were histidine or adenine deficient 
were obtained. Histidine prototrophy was easily reconstituted by transforming his-
defective diploid derivatives with yeast plasmids carrying the HIS3 gene. Despite dif-
ferent attempts, for example, by creating a rme1::KANX rme1::NATR double-deleted S. 
boulardii yeast strain (RME1 encodes for Regulator of Meiosis), no visible sporulation 
to obtain haploid derivatives could be obtained. Besides, no filamentation properties of 
S. boulardii were observed. As previously mentioned, this yeast strain was confirmed to 
thrive at 37°C, a temperature disliked by some but not all S. cerevisiae strains used in the 
laboratory. S. boulardii is a diploid derivative of S. cerevisiae that does not sporulates and 
survives at temperatures as those found in the human gut. It can be easily manipulated 
by using conventional yeast methods to introduce auxotrophic markers and obtain het-
erozygous diploid knockout derivatives that can be transformed with yeast plasmids 
following conventional yeast protocols, thereby it could be even suited for biochemical 
and genetic research purposes.
Keywords: Saccharomyces cerevisiae, Saccharomyces boulardii, probiotic, genetic properties, 
yeast transformation
1. Introduction
The French microbiologist Henry Boulard isolated in 1923 a yeast strain (later named after 
him) after observing natives in Indochina affected by digestive disorders to chew litchi and 
mangosteen skins. It was said (but never proven) that those people could even protect them-
selves thereby against outbreaks of cholera.
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Ever since, there has been an increasing body of medical reports addressing the beneficial 
properties of Saccharomyces boulardii as a probiotic to treat cases of diarrhea, reconstituting 
the gut flora after antibiotic treatment and even in the treatment of patients suffering from 
Helicobacter pylori that can cause stomach ulcers (for a recent review, see [1]). High doses 
of lyophilized living cells (2–5 × 109) are administered in pills that dissolve in the gastro-
intestinal tract. It is assumed that S. boulardii cells do not establish in the gastrointestinal 
tract and are secreted with the feces. Therefore, several doses are recommended to be taken 
during several days. It has not been clearly shown if on their passage yeast cells interact 
with other microorganisms in the gastrointestinal tract. Despite several clinical studies 
indicating beneficial effects of S. boulardii, there have been also reports identifying it as 
the cause of fungemia in hospital patients (adults and children) that had received doses of 
this yeast to treat gastrointestinal disorders [2]. Though the beneficial effects of the baker’s 
yeast S. cerevisiae used for fermentation are unquestioned, certain wild S. cerevisiae isolates 
can have negative effects especially in people with a compromised immunosystem after 
undergoing surgery. Non-domesticated yeast strains as those isolated in hospitals can have 
invasive properties very different from those observed for domesticated yeast strains used 
in bakeries and breweries.
Yeast strains used in the laboratory such as S288C are mostly derivatives of industrial yeast 
strains used for ages in breweries [3]. More recently, derivatives of diploid strain Σ1278b, 
which shows filamentous properties related to non-domesticated yeast strains [4], are used in 
molecular biology research. Surprisingly, the sequence identity of both yeast strains is only 
46% [5] indicating considerable genetic variability due to adaptation to differing milieus and 
to human domestication of this eukaryotic species [6].
Thanks to molecular genetic techniques, S. boulardii considered originally as a yeast species 
by itself [7] has been proven in recent years to be a variant of S. cerevisiae [8]. In this chapter, 
a diploid yeast strain similar to those strains used in most research laboratories, amenable to 
genetic manipulation when using conventional yeast protocols is shown.
2. Results
2.1. Growth properties of S. boulardii
To further characterize this yeast, its growth properties at different temperatures are com-
pared with other diploid yeast strains (all yeast strains used are summarized in Table 1). S. 
boulardii (I will keep this name in the text even though it is a S. cerevisiae strain) grows well on 
rich medium at 30°C as well as at 37°C but not at 40°C (Figure 1A). Growth at 37°C—though 
not ideal—is not uncommon to yeast strains such as the diploid strain BY4743 (a derivative 
of S288C) but as opposed to diploid strain RH2585/2586 (an Σ1278b derivative) which hardly 
grows at 37°C (Figure 1A). In that sense, growth at 37°C is not a particular and unique prop-
erty of S. boulardii. It probably rather reflects its accommodation to hot climates such as those 
found often in Indochina.
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A further investigated property is S. boulardii’s potential capability to form filaments. For this 
purpose, it was grown on SLAD plates which carry only limiting concentrations of ammo-
nium sulfate (50 μM, about 1000× less than conventional SD minimal medium). As observed 
under the microscope, the diploid strain RH2585/2586 clearly shows filamentous properties 
under such ammonium-limiting conditions (Figure 1B) [9]. Deletion of the FLO8 gene encod-
ing a transcriptional factor required for filamentation and adhesion completely abolished its 
filamentous properties. Flo8 is required to express, for example, Flo11, a cell-surface glyco-
protein [10]. As opposed to RH2585/2586, S. boulardii hardly showed any filamentation prop-
erties. Interestingly, sequencing of the PCR-amplified FLO8 gene of S. boulardii indicated that 
it does not carry a premature stop codon (not shown) found in non-filamentous yeast strains 
as those derived from S288C [10]. So, other up- or downstream genes required for filamenta-
tion are likely dysfunctional in S. boulardii. Its lack of filamentation probably explains its low 
toxicity and its lack of establishment capacity in the gastrointestinal tract that otherwise could 
make it more persistent and thereby more problematic for medical applications.
Another interesting issue was to induce meiosis and sporulation in S. boulardii in order to 
obtain haploid progeny. For this purpose, diploid cells were incubated in a liquid medium 
with limiting nitrogen and very high potassium acetate concentration as a (poor) carbon 
source [11]. Despite several attempts, no tetrad formation was observed. In that respect, S. 
boulardii shows similar properties as RH2585/2586 (the filamentous diploid used in this work) 
that does not form tetrads upon treatment under the described conditions. In order to induce 
meiosis and sporulation, a double knockout of RME1 (Regulator of Meiosis 1) in S. boular-
dii was produced. RME1 is a negative regulator of meiosis that prevents the expression of 
meiosis-required proteins such as IME1 (Inducer of Meiosis 1) and promotes mitosis [12]. 
The S. boulardii ∆∆rme1 derivative did not show any phenotypical differences to the parental 
wild-type strain in terms of growth temperature (Figure 1A). Unfortunately, no tetrads were 
obtained from this knockout strain either. I conclude that S. boulardii does not undergo meio-
sis and haploid tetrad formation at least under laboratory conditions used here.
Name and properties of diploid yeast strain Auxotrophic properties/antibiotic resistances
BY4743 Requires histidine, leucine, methionine, and uracil
RH2585/2586 Requires histidine and uracil
RH2585/2586 ∆flo8::kanX ∆flo8::NATR No requirements; G418- and NAT-resistant
S. boulardii None
S. boulardii ∆flo8::kanX ∆flo8::NATR No requirements; G418- and NAT-resistant
S. boulardii ∆rem1::kanX ∆rem1::NATR No requirements; G418- and NAT-resistant
S. boulardii ∆his3::kanX ∆his3::NATR Requires histidine; G418- and NAT-resistant
S. boulardii ∆ade2::kanX ∆ade2::NATR Requires adenine; G418- and NAT-resistant
G418/geneticin and NAT/nourseothricin are selective antibiotics for yeast strains.
Table 1. Diploid yeast strains used in this work.
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As shown in Figure 1C, S. boulardii does not carry any auxotrophic markers as it grows well 
on minimal medium (SD) devoid of amino acids or nucleic acid components such as adenine 
or uracil. Auxotrophic marker genes could be easily obtained by deleting the ADE2 (ade-
nine biosynthesis) or HIS3 (histidine biosynthesis) genes (Figure 1C). These deletions were 
obtained by introducing dominant auxotrophic marker genes that provide resistance to the 
antibiotics kanamycin/G418 or nourseothricin. Deletion of a single gene copy of ADE2 or 
HIS3 still allowed for growth on minimal medium plates (not shown) indicating the clear dip-
loid character of this yeast. Only double deletion of both HIS3- or ADE2-gene copies (which 
made it resistant against both kanamycin/G418 and nourseothricin; Figure 1C) made this 
yeast strain auxotrophic for histidine or for adenine. Newly gained histidine auxotrophy was 
used in a subsequent experiment to transform it with yeast plasmids carrying HIS3 as a select-
able marker gene (see subsequent text).
2.2. Transformation of S. boulardii with conventional yeast plasmids
As an auxotrophic histidine-deficient yeast strain was now available, I decided to transform 
it with conventional yeast plasmids that complement for the lack of HIS3. For this purpose, 
S. boulardii ∆∆his3 (#1811) was grown in minimal SD medium supplemented with histidine. 
Cells were made competent by treating them with Li-acetate following a well-established 
yeast transformation protocol [13].
Figure 1. Properties of S. boulardii and other diploid yeast strains (all listed in Table 1). (A) Growth comparison of 
yeast strains at different temperatures. Indicated yeast strains were spread on YPD plates and incubated at indicated 
temperatures (30, 37, and 40°C) for 2 days; (B) filamentation properties of different yeast strains. Strains RH2585/2586, 
RH2585/2586 ∆flo8::kanX ∆flo8::NATR, and S. boulardii were incubated on SLAD plates (50 μM ammonium sulfate) for 
1 day at 30°C and individual growth colony visualized under the microscope (upper panel: 20× magnification; lower 
panel: 100× magnification); (C) growth of S. boulardii on different media. S. boulardii (#1785) and derivatives ∆∆his3 
(#1811) and ∆∆ade2 (#1812) were grown for 2 days at 30°C on minimal SD medium (left plate) or on YPD + G418 and 
nourseothricin (both at final 100 μg/ml) (right plate). Denote the characteristic pinkish color of strain #1812 due to the 
deletion of both ADE2 gene copies.
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After 2–3 days of incubation at 30°C, his+-transformants were nicely observed (Figure 2; left 
panel), indicating that a simple yeast transformation protocol was sufficient to transform 
this yeast strain and to recover its prototrophy. Plasmids used for transformation (p301HIS3 
GAL-p20-HA from S. cerevisiae and Candida albicans) allow for the expression of the protein 
p20 (a modulator of the activity of eIF4E, the cap-binding protein; see subsequent text) when 
growing cells in a medium containing galactose. As shown on a Western Blot obtained from 
yeast extracts, p20 from different sources was expressed in galactose but not in glucose-
containing media (Figure 2; right panel). This confirms that, in S. boulardii, the GAL1/10 
promoter is regulated in an identical manner as in conventional yeast strains used in the 
laboratory [14].
2.3. Sequencing and comparison of S. boulardii p20 gene
p20, a small acidic protein of 161 amino acids, is encoded by the non-essential gene CAF20 
which only exists in a variety of yeast species (such as S. glabrata, Kluyveromyces lactis, C. 
albicans, S. cerevisiae). Its function is related to regulating the activity of the cap-binding 
protein eIF4E during translation in a yet not-well-understood manner [15]. A sequence 
alignment of different yeast species (see Figure 3; upper panel) shows a clear homol-
ogy but not identity of the corresponding p20 proteins. Especially conserved are peptide 
motifs at the amino terminus (which are required for binding to eIF4E; the canonical motif 
YxxxxLL/I/F highlighted) and at the carboxy terminus (where precise function has still to 
be determined).
Figure 2. Transformation of S. boulardii ∆∆his3 and expression of p20. (Left panel) Transformation of S. boulardii ∆∆his3. 
S. boulardii ∆∆his3 was transformed with plasmid p301HIS3 p20 (S. cerevisiae)-HA (segment 2) or with plasmid p301HIS3 
p20 (C. albicans)-HA (segment 3) and grown on minimal medium plates (without histidine) for 3 days at 27°C. As a 
negative control, no plasmid DNA was added (segment 1); (right panel) expression of HA-tagged p20 after induction 
with galactose. S. boulardii ∆∆his3 extracts from cells transformed with p301HIS3 p20 (S. cerevisiae)-HA (lanes 1 and 
3) or transformed with p301HIS3 p20 (C. albicans)-HA (lanes 2 and 4) grown on medium containing 2% glucose or 
2% galactose as indicated are shown. Individual colonies from segments 2 and 3 were picked and grown in liquid SD 
medium for 24 h. Subsequently, half of the cells were collected, washed (2× with water), resuspended in SGal (minimal 
medium with 2% galactose), and incubated for 24 h at 27°C. Collected cells were boiled in 2× SDS-sample buffer, proteins 
separated on a 15% SDS-PAGE gel. Separated proteins were blotted onto nitrocellulose, subsequently incubated with 
monoclonal antibodies against the HA-tag (1:2000 Dilution in 2% skim milk). For visualization of the Western Blot, 
WesternBright ECL kit (advansta) was used.
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The CAF20 gene from S. boulardii was PCR-amplified using genomic DNA and oligonucle-
otides hybridizing at the 5′ and 3′ region of the S. cerevisiae CAF20 gene. Subsequent sequenc-
ing showed that CAF20 from S. cerevisiae and S. boulardii is nearly identical. The only difference 
detected is a conserved amino acid substitution (leucine to valine; highlighted) at position 16 
(Figure 3; lower panel). Among those yeast species that carry the p20 gene conservation varies 
between 30 and 90% (not shown). The almost identity of both sequences shown here clearly 
confirms that S. boulardii is a variant of the species S. cerevisiae.
3. Conclusions
In this work, I present data indicating that S. boulardii is a diploid S. cerevisiae strain. It thrives 
well under laboratory conditions at different temperatures (up to 37°C) which is not unusual 
for different laboratory yeast strains. S. boulardii does not show filamentous properties even 
though its FLO8 gene does not carry the typical premature stop codon identified in many 
laboratory (and industrial) yeast strains. S. boulardii does not undergo meiosis or form hap-
loid progeny when incubated in sporulation-inducing media. S. boulardii does not carry 
any identifiable auxotrophic gene markers. It can be easily manipulated to obtain knockout 
Figure 3. Sequence comparison of p20 from different yeast species. Multiple sequence alignment of p20 from different 
yeast sources (CANGA, Candida glabrata; KLUYV, Kluyveromyces lactis; CANAL, Candida albicans; YEAST, Saccharomyces 
cerevisiae) was done with the help of Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Highlighted amino 
acids; see text. For sequencing of S. boulardii p20 gene, the complete ORF and adjacent sequences were PCR-amplified 
with oligonucleotides used for S. cerevisiae p20 gene amplification and the obtained PCR product was sequenced in both 
directions (shown is the part encoding the p20 open reading frame of S. boulardii).
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derivatives by inserting genes conferring antibiotic resistance and obtain thereby auxotrophic 
progeny. Additionally, S. boulardii can be easily transformed with conventional yeast plas-
mids allowing also for the expression of proteins regulated by the galactose-inducible GAL 
1/10 yeast promoter.
In accordance with those properties, it is probably not detrimental for human health (at least 
not for immunocompetent individuals) as it will not easily establish in the gut or penetrate the 
intestinal blood barrier. All this does not mean that it has beneficial physiological properties 
and I would like to ask the question: is this not just a further conventional yeast strain?
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